Demand – and concern – is growing for the newest generation of weight loss drugs. Approved by the FDA to treat type 2 diabetes, drugs like Ozempic and Wegovy have set off a media frenzy as celebrities and the wealthy touted their weight loss benefits. Leaders have a lot of questions about protocol, supply, and coverage of these drugs, and the consequences of patients using them for their unintended purpose. In this episode, host Rachel (Rae) Woods walks through these questions with experts Kara Marlatt, Gaby Marmolejos, and Chloe Bakst and discuss the potential future of weight management in US healthcare.

Links:

Learn more about Advisory Board Sponsorship opportunities at advisory.com/sponsorship